oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2024-23-5-157-169oncotomsk-3283Research ArticleОБЗОРЫREVIEWSФундаментальные аспекты биохимии селена и селенопротеинов: прикладное значение в онкологииFundamental aspects of selenium and selenoprotein biochemistry: applied value in oncologyhttps://orcid.org/0000-0002-9681-672XСтаноевичИ. В.StanoevichI. V.

Станоевич Ирина Васильевна, доктор медицинских наук, доцент, профессор кафедры онкологии, 305041, г. Курск, ул. Карла Маркса, 3;

акушер-гинеколог отдела эндокринной хирургии Института клинической эндокринологии, 117292, г. Москва, ул. Дмитрия Ульянова, 11

Irina V. Stanoevich, MD, DSc, Associate Professor, Professor, Department of Oncology, 3, Karl Marx St., Kursk, 305004;

Obstetrician-gynecologist, 113, Dmitry Ulyanov St., Moscow, 117292

https://orcid.org/0000-0003-3841-4164ХвостовойВ. В.KhvostovoyV. V.

Хвостовой Владимир Владимирович, кандидат медицинских наук, доцент, заведующий кафедрой онкологии, 305041, г. Курск, ул. Карла Маркса, 3;

онколог отделения опухолей кожи, костей и мягких тканей, 305524, Курская обл., Курский р-он, Рышковский с/с, х. Кислино, ул. Елисеева, 1

Vladimir V. Khvostovoy, MD, PhD, Associate Professor, Head of the Department of Oncology, 3, Karl Marx St., Kursk, 305004;

Oncologist, Department of Skin, Bone and Soft Tissue Tumors, 1, Eliseeva, Kursk, 305524

https://orcid.org/0000-0001-7910-5611ПетроченкоД. В.PetrochenkoD. V.

Петроченко Дмитрий Владимирович, аспирант кафедры онкологии, 305041, г. Курск, ул. Карла Маркса, 3;

онколог круглосуточного стационара противоопухолевой лекарственной терапии, 305524, Курская обл., Курский р-он, Рышковский с/с, х. Кислино, ул. Елисеева, 1

Dmitry V. Petrochenko, MD, Postgraduate, Department of Oncology, 3, Karl Marx St., Kursk, 305004;

Oncologist, round-the-clock hospital for antitumor drug therapy, 1, Eliseeva, Kursk, 305524

petrochenko.dima@yandex.ruhttps://orcid.org/0000-0001-7502-6764СаламатинаА. Ю.SalamatinaA. Yu.

Саламатина Анна Юрьевна, ведущий инженер химико-токсикологического отдела, 

305003, г. Курск, пер. Верхнеказацкий, 9

Anna Yu. Salamatina, Leading Engineer, Chemical and Toxicological Department,

9, Verkhnekazatsky per., Kursk, 305003

https://orcid.org/0000-0001-9002-1662ИоутсиВ. А.IoutsiV. A.

Иоутси Виталий Алексеевич, заведующий лабораторией метаболомных исследований,

117292, г. Москва, ул. Дмитрия Ульянова, 11

Vitaly A. Ioutsi, Head of the Laboratory for Metabolomics Research,

113, Dmitry Ulyanov St., Moscow, 117292

https://orcid.org/0000-0002-4627-7924ФурманЮ. В.FurmanYu V.

Фурман Юрий Васильевич , доктор биологических наук, профессор, старший научный сотрудник НИИ экспериментальной медицины, 

305041, г. Курск, ул. Карла Маркса, 3

Yuri V. Furman, DSc, Professor, Senior Researcher, Research Institute of Experimental Medicine, 

3, Karl Marx St., Kursk, 305004

https://orcid.org/0000-0001-7747-2784ЛысоволенкоН. Л.LysovolenkoN. L.

Лысоволенко Наталья Леонидовна, заведующая отделением функциональной диагностики и кардиотерапевтической помощи,

305524, Курская обл., Курский р-он, Рышковский с/с, х. Кислино, ул. Елисеева, 1

Natalya L. Lysovolenko, Head of the Department of Functional Diagnostics and Cardiac Care, 

1, Eliseeva, Kursk, 305524

https://orcid.org/0000-0002-3436-377XЕрмиловИ. В.ErmilovI. V.

Ермилов Иван Валерьевич, директор, 

305003, г. Курск, пер. Верхнеказацкий, 9

Ivan V. Ermilov, Director, 

9, Verkhnekazatsky per., Kursk, 305003

ФГБОУ ВО «Курский государственный медицинский университет» Минздрава России; ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииРоссияKursk State Medical University of the Ministry of Health of Russia; Endocrinology Research Center of the Ministry of Health of RussiaRussian FederationФГБОУ ВО «Курский государственный медицинский университет» Минздрава России; ОБУЗ «Курский онкологический научно-клинический центр им. Г.Е. Островерхова»РоссияKursk State Medical University of the Ministry of Health of Russia; G.E. Ostroverkhov Kursk Cancer Research and Clinical CenterRussian FederationОБУ «Курская областная ветеринарная лаборатория»РоссияKursk Regional Veterinary LaboratoryRussian FederationФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииРоссияEndocrinology Research Center of the Ministry of Health of RussiaRussian FederationФГБОУ ВО «Курский государственный медицинский университет» Минздрава РоссииРоссияKursk State Medical University of the Ministry of Health of RussiaRussian FederationОБУЗ «Курский онкологический научно-клинический центр им. Г.Е. Островерхова»РоссияG.E. Ostroverkhov Kursk Cancer Research and Clinical CenterRussian Federation202415112024235157169Copyright © Станоевич И.В., Хвостовой В.В., Петроченко Д.В., Саламатина А.Ю., Иоутси В.А., Фурман Ю.В., Лысоволенко Н.Л., Ермилов И.В., 20242024Станоевич И.В., Хвостовой В.В., Петроченко Д.В., Саламатина А.Ю., Иоутси В.А., Фурман Ю.В., Лысоволенко Н.Л., Ермилов И.В.Stanoevich I.V., Khvostovoy V.V., Petrochenko D.V., Salamatina A.Y., Ioutsi V.A., Furman Y.V., Lysovolenko N.L., Ermilov I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/3283

Цель исследования – провести систематический анализ данных, имеющихся в современной литературе об эссенциальности селена в биологических системах и значении селенопротеинов в онкогенезе.

Материал и методы

Материал и методы. При подготовке обзора проведен поиск публикаций в информационных базах Scopus (415), PubMed (521), Web of Science (139), eLibrary.ru (240). Для получения полнотекстовых документов использованы электронные ресурсы PubMed Central (PMC), Science Direct, Research Gate, eLibrary.ru.

Результаты

Результаты. Необходимость применения соединений селена с целью профилактики и лечения злокачественных новообразований носит неоднозначный характер, а некоторые селенопротеины продемонстрировали пермиссивную роль в онкогенезе, что требует дальнейшего углубленного изучения вопроса.

Заключение

Заключение. Необходимо продолжать комплексные молекулярные исследования биоорганических соединений селена на морфологическом, ультраструктурном и биохимическом уровнях при опухолях различных локализаций в зависимости от генетических особенностей изучаемой популяции и геохимических характеристик региона.

The purpose of the study was to carry out a systematic analysis of the data available in the modern literature on the essentiality of selenium in biological systems and the importance of selenoproteins in oncogenesis.

Material and Methods

Material and Methods. The publications were analyzed using Scopus (415), PubMed (521), Web of Science (139), eLibrary.ru (240) databases. To obtain full-text documents, the electronic resources PubMed Central (PMC), Science Direct, Research Gate, eLibrary.ru were used.

Results

Results. The need to use selenium compounds for the prevention and treatment of malignant neoplasms is controversial, and some selenoproteins have demonstrated a permissive role in oncogenesis, thus requiring further in-depth study in neoplasms of various histogenesis.

Conclusion

Conclusion. It is necessary to continue comprehensive molecular studies of bioorganic selenium compounds at the morphological, ultrastructural and biochemical levels in tumors of various localizations, depending on the genetic characteristics of the studied population and the geochemical characteristics of the region.

селенселенопротеиныонкогенезопухольхимиотерапияseleniumselenoproteinsoncogenesistumorchemotherapyReferencesKurokawa S., Berry M.J. Selenium. Role of the essential metalloid in health. Met Ions Life Sci. 2013; 13: 499–534. doi: 10.1007/978-94-007-7500-8_16.Kurokawa S., Berry M.J. Selenium. Role of the essential metalloid in health. Met Ions Life Sci. 2013; 13: 499–534. doi: 10.1007/978-94-007-7500-8_16.Kozlov A.P. Evolution by Tumor Neofunctionalization: the role of tumors in the origin of new cell types, tissues and organs. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney and Tokyo: Academic Press/Elsevier; 2014. 248 p.Kozlov A.P. Evolution by Tumor Neofunctionalization: the role of tumors in the origin of new cell types, tissues and organs. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney and Tokyo: Academic Press/Elsevier; 2014. 248 p.Elhodaky M., Diamond A.M. Selenium-Binding Protein 1 in Human Health and Disease. Int J Mol Sci. 2018; 19(11): 3437. doi: 10.3390/ijms19113437.Elhodaky M., Diamond A.M. Selenium-Binding Protein 1 in Human Health and Disease. Int J Mol Sci. 2018; 19(11): 3437. doi: 10.3390/ijms19113437.Ying Q., Ansong E., Diamond A.M., Yang W. A Critical Role for Cysteine 57 in the Biological Functions of Selenium Binding Protein-1. Int J Mol Sci. 2015; 16(11): 27599–608. doi: 10.3390/ijms161126043.Ying Q., Ansong E., Diamond A.M., Yang W. A Critical Role for Cysteine 57 in the Biological Functions of Selenium Binding Protein-1. Int J Mol Sci. 2015; 16(11): 27599–608. doi: 10.3390/ijms161126043.Minich W.B. Selenium Metabolism and Biosynthesis of Selenoproteins in the Human Body. Biochemistry (Mosc). 2022; 87(s1). doi: 10.1134/S0006297922140139.Minich W.B. Selenium Metabolism and Biosynthesis of Selenoproteins in the Human Body. Biochemistry (Mosc). 2022; 87(s1). doi: 10.1134/S0006297922140139.Авцын А.П., Жаворонков А.А., Риш М.А., Строчкова Л.С. Микроэлементозы человека. М., 1991. С. 126–44.Avtsyn A.P., Zhavoronkov A.A., Rish M.A., Strochkova L.S. Human microelementoses. Moscow, 1991. P. 126–44. (in Russian).Kieliszek M. Selenium. Chapter Eleven. Advances in food and nutrition research. 2021; 96: 417–29. doi: 10.1016/bs.afnr.2021.02.019.Kieliszek M. Selenium. Chapter Eleven. Advances in food and nutrition research. 2021; 96: 417–29. doi: 10.1016/bs.afnr.2021.02.019.Барановский А.Ю. Диетология. 5-е издание. СПб., 2017. 1104 с.Baranovsky A.Yu. Dietetics. 5th ed. St. Petersburg, 2017. 1104 p. (in Russian).Wang P., Chen B., Huang Y., Li J., Cao D., Chen Z., Li J., Ran B., Yang J., Wang R., Wei Q., Dong Q., Liu L. Selenium intake and multiple health-related outcomes: an umbrella review of meta-analyses. Front Nutr. 2023; 10. doi: 10.3389/fnut.2023.1263853.Wang P., Chen B., Huang Y., Li J., Cao D., Chen Z., Li J., Ran B., Yang J., Wang R., Wei Q., Dong Q., Liu L. Selenium intake and multiple health-related outcomes: an umbrella review of meta-analyses. Front Nutr. 2023; 10. doi: 10.3389/fnut.2023.1263853.Rayman M.P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005; 64(4): 527–42. doi: 10.1079/pns2005467.Rayman M.P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005; 64(4): 527–42. doi: 10.1079/pns2005467.Povey S., Lovering R., Bruford E., Wright M., Lush M., Wain H. The HUGO Gene Nomenclature Committee (HGNC). Hum Genet. 2001; 109(6): 678–80. doi: 10.1007/s00439-001-0615-0.Povey S., Lovering R., Bruford E., Wright M., Lush M., Wain H. The HUGO Gene Nomenclature Committee (HGNC). Hum Genet. 2001; 109(6): 678–80. doi: 10.1007/s00439-001-0615-0.Gladyshev V.N., Arnér E.S., Berry M.J., Brigelius-Flohé R., Bruford E.A., Burk R.F., Carlson B.A., Castellano S., Chavatte L., Conrad M., Copeland P.R., Diamond A.M., Driscoll D.M., Ferreiro A., Flohé L., Green F.R., Guigó R., Handy D.E., Hatfeld D.L., Hesketh J., Hoffmann P.R., Holmgren A., Hondal R.J., Howard M.T., Huang K., Kim H.Y., Kim I.Y., Köhrle J., Krol A., Kryukov G.V., Lee B.J., Lee B.C., Lei X.G., Liu Q., Lescure A., Lobanov A.V., Loscalzo J., Maiorino M., Mariotti M., Sandeep Prabhu K., Rayman M.P., Rozovsky S., Salinas G., Schmidt E.E., Schomburg L., Schweizer U., Simonović M., Sunde R.A., Tsuji P.A., Tweedie S., Ursini F., Whanger P.D., Zhang Y. Selenoprotein Gene Nomenclature. J Biol Chem. 2016; 291(46): 24036–40. doi: 10.1074/jbc.M116.756155.Gladyshev V.N., Arnér E.S., Berry M.J., Brigelius-Flohé R., Bruford E.A., Burk R.F., Carlson B.A., Castellano S., Chavatte L., Conrad M., Copeland P.R., Diamond A.M., Driscoll D.M., Ferreiro A., Flohé L., Green F.R., Guigó R., Handy D.E., Hatfeld D.L., Hesketh J., Hoffmann P.R., Holmgren A., Hondal R.J., Howard M.T., Huang K., Kim H.Y., Kim I.Y., Köhrle J., Krol A., Kryukov G.V., Lee B.J., Lee B.C., Lei X.G., Liu Q., Lescure A., Lobanov A.V., Loscalzo J., Maiorino M., Mariotti M., Sandeep Prabhu K., Rayman M.P., Rozovsky S., Salinas G., Schmidt E.E., Schomburg L., Schweizer U., Simonović M., Sunde R.A., Tsuji P.A., Tweedie S., Ursini F., Whanger P.D., Zhang Y. Selenoprotein Gene Nomenclature. J Biol Chem. 2016; 291(46): 24036–40. doi: 10.1074/jbc.M116.756155.Голубкина Н.А., Папазян Т.Т. Селен в питании: растения, животные, человек. М., 2006. 254 с.Golubkina N.A., Papazyan T.T. Selenium in nutrition: plants, animals, humans. Moscow, 2006. 254 p. (in Russian).Sword J.T., Pope A.L., Hoekstra W.G. Endotoxin and lipid peroxidation in vitro in selenium- and vitamin E-defcient and -adequate rat tissues. J Nutr. 1991; 121(2): 258–64. doi: 10.1093/jn/121.2.258.Sword J.T., Pope A.L., Hoekstra W.G. Endotoxin and lipid peroxidation in vitro in selenium- and vitamin E-defcient and -adequate rat tissues. J Nutr. 1991; 121(2): 258–64. doi: 10.1093/jn/121.2.258.Shreenath A.P., Hashmi M.F., Dooley J. Selenium Defciency. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.Shreenath A.P., Hashmi M.F., Dooley J. Selenium Defciency. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.Burk R.F., Olson G.E., Hill K.E. Deletion of selenoprotein P gene in the mouse. Selenium: its molecular biology and role in human health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 111–122.Burk R.F., Olson G.E., Hill K.E. Deletion of selenoprotein P gene in the mouse. Selenium: its molecular biology and role in human health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 111–122.Варламова Е.Г., Гольтяев М.В., Новоселов С.В., Новоселов В.И., Фесенко Е.Е. Биосинтез и механизм встраивания селеноцистеина в синтезируемые белки. Молекулярная биология. 2013; 47(4): 558–67. doi: 10.7868/S0026898413040137.Varlamova E.G., Goltiaev M.V., Novocelov S.V., Novoselov V.I., Fecenko E.E. Biosyinthesis and mechanism of selenocysteine incorporation into synthesized proteins. Mol Biol (Mosk). 2013; 47(4): 558–67. (in Russian). doi: 10.7868/S0026898413040137.Genchi G., Lauria G., Catalano A., Sinicropi M.S., Carocci A. Biological Activity of Selenium and Its Impact on Human Health. Int J Mol Sci. 2023; 24(3): 2633. doi: 10.3390/ijms24032633.Genchi G., Lauria G., Catalano A., Sinicropi M.S., Carocci A. Biological Activity of Selenium and Its Impact on Human Health. Int J Mol Sci. 2023; 24(3): 2633. doi: 10.3390/ijms24032633.Seko Y., Saito Y., Kitahara J., Imura N. Active Oxygen Generation by the Reaction of Selenite with Reduced Glutathione in Vitro. In: Selenium in Biology and Medicine. Eds. Wendel A. Heidelberg. Springer, 1989: 70–73.Seko Y., Saito Y., Kitahara J., Imura N. Active Oxygen Generation by the Reaction of Selenite with Reduced Glutathione in Vitro. In: Selenium in Biology and Medicine. Eds. Wendel A. Heidelberg. Springer, 1989: 70–73.Кудрин А.В., Громова О.А. Микроэлементы в иммуннологии и онкологии. М., 2007. 544 с.Kudrin A.V., Gromova O.A. Microelements and immunology and oncology. Moscow, 2007. 544 p. (in Russian).Chiu-Ugalde J., Theilig F., Behrends T., Drebes J., Sieland C., Subbarayal P., Köhrle J., Hammes A., Schomburg L., Schweizer U. Mutation of megalin leads to urinary loss of selenoprotein P and selenium defciency in serum, liver, kidneys and brain. Biochem J. 2010; 431(1): 103–11. doi: 10.1042/BJ20100779.Chiu-Ugalde J., Theilig F., Behrends T., Drebes J., Sieland C., Subbarayal P., Köhrle J., Hammes A., Schomburg L., Schweizer U. Mutation of megalin leads to urinary loss of selenoprotein P and selenium defciency in serum, liver, kidneys and brain. Biochem J. 2010; 431(1): 103–11. doi: 10.1042/BJ20100779.Русецкая Н.Ю. Гипотетическая связь между метаболизмом селена и углеводным обменом. Современные проблемы науки и образования. 2014; (2): 488.Rusetskaya N.Yu. Hypothetical connection between selenium metabolism and carbohydrate metabolism. Modern Problems of Science and Education. 2014; (2): 488. (in Russian).Vinceti M., Filippini T., Del Giovane C., Dennert G., Zwahlen M., Brinkman M., Zeegers M.P., Horneber M., D’Amico R., Crespi C.M. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018; 1(1). doi: 10.1002/14651858.CD005195.pub4.Vinceti M., Filippini T., Del Giovane C., Dennert G., Zwahlen M., Brinkman M., Zeegers M.P., Horneber M., D’Amico R., Crespi C.M. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018; 1(1). doi: 10.1002/14651858.CD005195.pub4.Kadkol S., Diamond A.M. The Interaction between Dietary Selenium Intake and Genetics in Determining Cancer Risk and Outcome. Nutrients. 2020; 12(8): 2424. doi: 10.3390/nu12082424.Kadkol S., Diamond A.M. The Interaction between Dietary Selenium Intake and Genetics in Determining Cancer Risk and Outcome. Nutrients. 2020; 12(8): 2424. doi: 10.3390/nu12082424.Ursini F., Heim S., Kiess M., Maiorino M., Roveri A., Wissing J., Flohé L. Dual function of the selenoprotein PHGPx during sperm maturation. Science. 1999; 285(5432): 1393–6. doi: 10.1126/science.285.5432.1393.Ursini F., Heim S., Kiess M., Maiorino M., Roveri A., Wissing J., Flohé L. Dual function of the selenoprotein PHGPx during sperm maturation. Science. 1999; 285(5432): 1393–6. doi: 10.1126/science.285.5432.1393.Mustacich D., Powis G. Thioredoxin reductase. Biochem J. 2000; 346 Pt 1(Pt 1): 1–8.Mustacich D., Powis G. Thioredoxin reductase. Biochem J. 2000; 346 Pt 1(Pt 1): 1–8.Bianco A.C., Larsen P.R. Selenium, deiodinases and endocrine function. Selenium: Its Molecular Biology and Role in Human Health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 207–219. doi: 10.1007/0-387-33827-6_19.Bianco A.C., Larsen P.R. Selenium, deiodinases and endocrine function. Selenium: Its Molecular Biology and Role in Human Health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 207–219. doi: 10.1007/0-387-33827-6_19.Arteel G.E., Briviba K., Sies H. Protection against peroxynitrite. FEBS Lett. 1999; 445(2–3): 226–30. doi: 10.1016/s0014-5793-(99)00073-3.Arteel G.E., Briviba K., Sies H. Protection against peroxynitrite. FEBS Lett. 1999; 445(2–3): 226–30. doi: 10.1016/s0014-5793-(99)00073-3.Kioussi C., Whanger P.D. Selenoprotein W in development and oxidative stress. Selenium: Its Molecular Biology and Role in Human Health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 135–140.Kioussi C., Whanger P.D. Selenoprotein W in development and oxidative stress. Selenium: Its Molecular Biology and Role in Human Health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 135–140.Gu Q.P., Beilstein M.A., Vendeland S.C., Lugade A., Ream W., Whanger P.D. Conserved features of selenocysteine insertion sequence (SECIS) elements in selenoprotein W cDNAs from fve species. Gene. 1997; 193(2): 187–96. doi: 10.1016/s0378-1119(97)00113-3.Gu Q.P., Beilstein M.A., Vendeland S.C., Lugade A., Ream W., Whanger P.D. Conserved features of selenocysteine insertion sequence (SECIS) elements in selenoprotein W cDNAs from fve species. Gene. 1997; 193(2): 187–96. doi: 10.1016/s0378-1119(97)00113-3.Kuria A., Fang X., Li M., Han H., He J., Aaseth J.O., Cao Y. Does dietary intake of selenium protect against cancer? A systematic review and meta-analysis of population-based prospective studies. Crit Rev Food Sci Nutr. 2020; 60(4): 684–94. doi: 10.1080/10408398.2018.1548427.Kuria A., Fang X., Li M., Han H., He J., Aaseth J.O., Cao Y. Does dietary intake of selenium protect against cancer? A systematic review and meta-analysis of population-based prospective studies. Crit Rev Food Sci Nutr. 2020; 60(4): 684–94. doi: 10.1080/10408398.2018.1548427.Bösl M.R., Takaku K., Oshima M., Nishimura S., Taketo M.M. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). Proc Natl Acad Sci USA. 1997; 94(11): 5531–34. doi: 10.1073/pnas.94.11.5531.Bösl M.R., Takaku K., Oshima M., Nishimura S., Taketo M.M. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). Proc Natl Acad Sci USA. 1997; 94(11): 5531–34. doi: 10.1073/pnas.94.11.5531.Lener M.R., Scott R.J., Wiechowska-Kozłowska A., SerranoFernández P., Baszuk P., Jaworska-Bieniek K., Sukiennicki G., Marciniak W., Muszyńska M., Kładny J., Gromowski T., Kaczmarek K., Jakubowska A., Lubiński J. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat. 2016; 48(3): 1056–64. doi: 10.4143/crt.2015.282.Lener M.R., Scott R.J., Wiechowska-Kozłowska A., SerranoFernández P., Baszuk P., Jaworska-Bieniek K., Sukiennicki G., Marciniak W., Muszyńska M., Kładny J., Gromowski T., Kaczmarek K., Jakubowska A., Lubiński J. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat. 2016; 48(3): 1056–64. doi: 10.4143/crt.2015.282.Jiang Z., Chi J., Li H., Wang Y., Liu W., Han B. Efect of chitosan oligosaccharide-conjugated selenium on improving immune function and blocking gastric cancer growth. Eur J Pharmacol. 2021; 891. doi: 10.1016/j.ejphar.2020.173673.Jiang Z., Chi J., Li H., Wang Y., Liu W., Han B. Efect of chitosan oligosaccharide-conjugated selenium on improving immune function and blocking gastric cancer growth. Eur J Pharmacol. 2021; 891. doi: 10.1016/j.ejphar.2020.173673.Augustyniak M., Galas A. Selenium dietary intake and survival among CRC patients. Int J Vitam Nutr Res. 2023; 93(6): 518–28. doi: 10.1024/0300-9831/a000768.Augustyniak M., Galas A. Selenium dietary intake and survival among CRC patients. Int J Vitam Nutr Res. 2023; 93(6): 518–28. doi: 10.1024/0300-9831/a000768.Wang Y., Fang W., Huang Y., Hu F., Ying Q., Yang W., Xiong B. Reduction of selenium-binding protein 1 sensitizes cancer cells to selenite via elevating extracellular glutathione: a novel mechanism of cancerspecifc cytotoxicity of selenite. Free Radic Biol Med. 2015; 79: 186–96. doi: 10.1016/j.freeradbiomed.2014.11.015.Wang Y., Fang W., Huang Y., Hu F., Ying Q., Yang W., Xiong B. Reduction of selenium-binding protein 1 sensitizes cancer cells to selenite via elevating extracellular glutathione: a novel mechanism of cancerspecifc cytotoxicity of selenite. Free Radic Biol Med. 2015; 79: 186–96. doi: 10.1016/j.freeradbiomed.2014.11.015.Radomska D., Czarnomysy R., Radomski D., Bielawska A., Bielawski K. Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity. Nutrients. 2021; 13(5): 1649. doi: 10.3390/nu13051649.Radomska D., Czarnomysy R., Radomski D., Bielawska A., Bielawski K. Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity. Nutrients. 2021; 13(5): 1649. doi: 10.3390/nu13051649.Brigelius-Flohé R., Kipp A.P. Glutathione Peroxidase 2, a Selenoprotein Exhibiting a Dual Personality in Preventing and Promoting Cancer. In Selenium. Its Molecular Biology and Role in Human Health, 4th ed. Springer International Publishing: New York, NY, USA, 2016; Chapter 38; P. 451–462. doi: 10.1007/978-3-319-41283-2_38.Brigelius-Flohé R., Kipp A.P. Glutathione Peroxidase 2, a Selenoprotein Exhibiting a Dual Personality in Preventing and Promoting Cancer. In Selenium. Its Molecular Biology and Role in Human Health, 4th ed. Springer International Publishing: New York, NY, USA, 2016; Chapter 38; P. 451–462. doi: 10.1007/978-3-319-41283-2_38.Bertz M., Kühn K., Koeberle S.C., Müller M.F., Hoelzer D., Thies K., Deubel S., Thierbach R., Kipp A.P. Selenoprotein H controls cell cycle progression and proliferation of human colorectal cancer cells. Free Radic Biol Med. 2018; 127: 98–107. doi: 10.1016/j.freeradbiomed.2018.01.010.Bertz M., Kühn K., Koeberle S.C., Müller M.F., Hoelzer D., Thies K., Deubel S., Thierbach R., Kipp A.P. Selenoprotein H controls cell cycle progression and proliferation of human colorectal cancer cells. Free Radic Biol Med. 2018; 127: 98–107. doi: 10.1016/j.freeradbiomed.2018.01.010.Shamberger R.J., Rudolph G. Protection against cocarcinogenesis by antioxidants. Experientia. 1966; 22(2): 116. doi: 10.1007/BF01900187.Shamberger R.J., Rudolph G. Protection against cocarcinogenesis by antioxidants. Experientia. 1966; 22(2): 116. doi: 10.1007/BF01900187.Clark L.C., Combs G.F. Jr., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., Davis L.S., Glover R.A., Graham G.F., Gross E.G., Krongrad A., Lesher J.L. Jr., Park H.K., Sanders B.B. Jr., Smith C.L., Taylor J.R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276(24): 1957–63.Clark L.C., Combs G.F. Jr., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., Davis L.S., Glover R.A., Graham G.F., Gross E.G., Krongrad A., Lesher J.L. Jr., Park H.K., Sanders B.B. Jr., Smith C.L., Taylor J.R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276(24): 1957–63.Zyambo K., Kelly P., Kayamba V. Evaluation of the association between gastric cancer and plasma selenium in Zambian adults: a casecontrol study. Ecancermedicalscience. 2022; 16: 1351. doi: 10.3332/ecancer.2022.1351.Zyambo K., Kelly P., Kayamba V. Evaluation of the association between gastric cancer and plasma selenium in Zambian adults: a casecontrol study. Ecancermedicalscience. 2022; 16: 1351. doi: 10.3332/ecancer.2022.1351.Zhu X., Pan D., Wang N., Wang S., Sun G. Relationship Between Selenium in Human Tissues and Breast Cancer: a Meta-analysis Based on Case-Control Studies. Biol Trace Elem Res. 2021; 199(12): 4439–46. doi: 10.1007/s12011-021-02574-9.Zhu X., Pan D., Wang N., Wang S., Sun G. Relationship Between Selenium in Human Tissues and Breast Cancer: a Meta-analysis Based on Case-Control Studies. Biol Trace Elem Res. 2021; 199(12): 4439–46. doi: 10.1007/s12011-021-02574-9.Bevinakoppamath S., Saleh Ahmed A.M., Ramachandra S.C., Vishwanath P., Prashant A. Chemopreventive and Anticancer Property of Selenoproteins in Obese Breast Cancer. Front Pharmacol. 2021; 12. doi: 10.3389/fphar.2021.618172.Bevinakoppamath S., Saleh Ahmed A.M., Ramachandra S.C., Vishwanath P., Prashant A. Chemopreventive and Anticancer Property of Selenoproteins in Obese Breast Cancer. Front Pharmacol. 2021; 12. doi: 10.3389/fphar.2021.618172.Wang L., Wang J., Liu X., Liu Q., Zhang G., Liang L. Association between selenium intake and the risk of pancreatic cancer: a metaanalysis of observational studies. Biosci Rep. 2016; 36(5). doi: 10.1042/BSR20160345.Wang L., Wang J., Liu X., Liu Q., Zhang G., Liang L. Association between selenium intake and the risk of pancreatic cancer: a metaanalysis of observational studies. Biosci Rep. 2016; 36(5). doi: 10.1042/BSR20160345.Gómez-Tomás Á., Pumarega J., Alguacil J., Amaral A.F.S., Malats N., Pallarès N., Gasull M., Porta M.; PANKRAS II Study Group. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. Environ Mol Mutagen. 2019; 60(8): 693–703. doi: 10.1002/em.22296.Gómez-Tomás Á., Pumarega J., Alguacil J., Amaral A.F.S., Malats N., Pallarès N., Gasull M., Porta M.; PANKRAS II Study Group. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. Environ Mol Mutagen. 2019; 60(8): 693–703. doi: 10.1002/em.22296.Janowska M., Potocka N., Paszek S., Skrzypa M., Wróbel A., Kluz M., Baszuk P., Marciniak W., Gronwald J., Lubiński J., Zawlik I., Kluz T. An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer. Nutrients. 2022; 14(5): 958. doi: 10.3390/nu14050958.Janowska M., Potocka N., Paszek S., Skrzypa M., Wróbel A., Kluz M., Baszuk P., Marciniak W., Gronwald J., Lubiński J., Zawlik I., Kluz T. An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer. Nutrients. 2022; 14(5): 958. doi: 10.3390/nu14050958.Yang W., Diamond A.M. Selenium-binding protein 1 as a tumor suppressor and a prognostic indicator of clinical outcome. Biomark Res. 2013; 1(1): 15. doi: 10.1186/2050-7771-1-15.Yang W., Diamond A.M. Selenium-binding protein 1 as a tumor suppressor and a prognostic indicator of clinical outcome. Biomark Res. 2013; 1(1): 15. doi: 10.1186/2050-7771-1-15.Meng Q., Xu J., Liang C., Liu J., Hua J., Zhang Y., Ni Q., Shi S., Yu X. GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Cell Death Dis. 2018; 9: 1187. doi: 10.1038/s41419-018-1244-z.Meng Q., Xu J., Liang C., Liu J., Hua J., Zhang Y., Ni Q., Shi S., Yu X. GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Cell Death Dis. 2018; 9: 1187. doi: 10.1038/s41419-018-1244-z.Li M., Cheng W., Nie T., Lai H., Hu X., Luo J., Li F., Li H. Selenoprotein K mediates the proliferation, migration, and invasion of human choriocarcinoma cells by negatively regulating human chorionic gonadotropin expression via ERK, P38 MAPK, and Akt signaling pathway. Biol. Trace Elem. Res. 2018; 184(1): 47–59. doi: 10.1007/s12011-017-1155-3.Li M., Cheng W., Nie T., Lai H., Hu X., Luo J., Li F., Li H. Selenoprotein K mediates the proliferation, migration, and invasion of human choriocarcinoma cells by negatively regulating human chorionic gonadotropin expression via ERK, P38 MAPK, and Akt signaling pathway. Biol. Trace Elem. Res. 2018; 184(1): 47–59. doi: 10.1007/s12011-017-1155-3.Zhang X.Y., Gao P.T., Yang X., Cai J.B., Ding G.Y., Zhu X.D., Ji Y., Shi G.M., Shen Y.H., Zhou J., Fan J., Sun H.C., Yang L.X,. Huang C. Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. Am J Transl Res. 2018; 10(11): 3567–78.Zhang X.Y., Gao P.T., Yang X., Cai J.B., Ding G.Y., Zhu X.D., Ji Y., Shi G.M., Shen Y.H., Zhou J., Fan J., Sun H.C., Yang L.X,. Huang C. Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. Am J Transl Res. 2018; 10(11): 3567–78.Hughes D.J., Kunická T., Schomburg L., Liška V., Swan N., Souček P. Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer. Nutrients. 2018; 10(11): 1812. doi: 10.3390/nu10111812.Hughes D.J., Kunická T., Schomburg L., Liška V., Swan N., Souček P. Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer. Nutrients. 2018; 10(11): 1812. doi: 10.3390/nu10111812.Wang Y., Zhu W., Chen X., Wei G., Jiang G., Zhang G. Seleniumbinding protein 1 transcriptionally activates p21 expression via p53- independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer. J Transl Med. 2020; 18(1): 17. doi: 10.1186/s12967-020-02211-4.Wang Y., Zhu W., Chen X., Wei G., Jiang G., Zhang G. Seleniumbinding protein 1 transcriptionally activates p21 expression via p53- independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer. J Transl Med. 2020; 18(1): 17. doi: 10.1186/s12967-020-02211-4.Song M., Kumaran M.N., Gounder M., Gibbon D.G., NievesNeira W., Vaidya A., Hellmann M., Kane M.P., Buckley B., Shih W., Caffrey P.B., Frenkel G.D., Rodriguez-Rodriguez L. Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecol Oncol. 2018; 150(3): 478–86. doi: 10.1016/j.ygyno.2018.07.001.Song M., Kumaran M.N., Gounder M., Gibbon D.G., NievesNeira W., Vaidya A., Hellmann M., Kane M.P., Buckley B., Shih W., Caffrey P.B., Frenkel G.D., Rodriguez-Rodriguez L. Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecol Oncol. 2018; 150(3): 478–86. doi: 10.1016/j.ygyno.2018.07.001.Hu Y.J., Chen Y., Zhang Y.Q., Zhou M.Z., Song X.M., Zhang B.Z., Luo L., Xu P.M., Zhao Y.N., Zhao Y.B., Cheng G. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997; 56(3): 331–41. doi: 10.1007/BF02785304.Hu Y.J., Chen Y., Zhang Y.Q., Zhou M.Z., Song X.M., Zhang B.Z., Luo L., Xu P.M., Zhao Y.N., Zhao Y.B., Cheng G. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997; 56(3): 331–41. doi: 10.1007/BF02785304.Lanfear J., Fleming J., Wu L., Webster G., Harrison P.R. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive efects of selenium? Carcinogenesis. 1994; 15(7): 1387–92. doi: 10.1093/carcin/15.7.1387.Lanfear J., Fleming J., Wu L., Webster G., Harrison P.R. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive efects of selenium? Carcinogenesis. 1994; 15(7): 1387–92. doi: 10.1093/carcin/15.7.1387.Goltyaev M.V., Maltseva V.N., Varlamova E.G. Expression of ERresident selenoproteins and activation of cancer cells apoptosis mechanisms under ER-stress conditions caused by methylseleninic acid. Gene. 2020; 755. doi: 10.1016/j.gene.2020.144884.Goltyaev M.V., Maltseva V.N., Varlamova E.G. Expression of ERresident selenoproteins and activation of cancer cells apoptosis mechanisms under ER-stress conditions caused by methylseleninic acid. Gene. 2020; 755. doi: 10.1016/j.gene.2020.144884.Shimada B.K., Swanson S., Toh P., Seale L.A. Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers. Biomolecules. 2022; 12(11): 1581. doi: 10.3390/biom12111581.Shimada B.K., Swanson S., Toh P., Seale L.A. Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers. Biomolecules. 2022; 12(11): 1581. doi: 10.3390/biom12111581.Kobayashi H., Yoshimoto C., Matsubara S., Shigetomi H., Imanaka S. A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer. Cancer Drug Resist. 2023; 6(3): 547–66. doi: 10.20517/cdr.2023.49.Kobayashi H., Yoshimoto C., Matsubara S., Shigetomi H., Imanaka S. A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer. Cancer Drug Resist. 2023; 6(3): 547–66. doi: 10.20517/cdr.2023.49.Li Z., Ferguson L., Deol K.K., Roberts M.A., Magtanong L., Hendricks J.M., Mousa G.A., Kilinc S., Schaefer K., Wells J.A., Bassik M.C., Goga A., Dixon S.J., Ingolia N.T., Olzmann J.A. Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. Nat Chem Biol. 2022; 18(7): 751–61. doi: 10.1038/s41589-022-01033-3.Li Z., Ferguson L., Deol K.K., Roberts M.A., Magtanong L., Hendricks J.M., Mousa G.A., Kilinc S., Schaefer K., Wells J.A., Bassik M.C., Goga A., Dixon S.J., Ingolia N.T., Olzmann J.A. Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. Nat Chem Biol. 2022; 18(7): 751–61. doi: 10.1038/s41589-022-01033-3.Sekhar K.R., Hanna D.N., Cyr S., Baechle J.J., Kuravi S., Balusu R., Rathmell K., Baregamian N. Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer. Sci Rep. 2022; 12(1). doi: 10.1038/s41598-022-23906-2.Sekhar K.R., Hanna D.N., Cyr S., Baechle J.J., Kuravi S., Balusu R., Rathmell K., Baregamian N. Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer. Sci Rep. 2022; 12(1). doi: 10.1038/s41598-022-23906-2.Santesmasses D., Gladyshev V.N. Selenocysteine Machinery Primarily Supports TXNRD1 and GPX4 Functions and Together They Are Functionally Linked with SCD and PRDX6. Biomolecules. 2022; 12(8): 1049. doi: 10.3390/biom12081049.Santesmasses D., Gladyshev V.N. Selenocysteine Machinery Primarily Supports TXNRD1 and GPX4 Functions and Together They Are Functionally Linked with SCD and PRDX6. Biomolecules. 2022; 12(8): 1049. doi: 10.3390/biom12081049.Fu B., Meng W., Zeng X., Zhao H., Liu W., Zhang T. TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma. BioMed Res. Int. 2017. doi: 10.1155/2017/4698167.Fu B., Meng W., Zeng X., Zhao H., Liu W., Zhang T. TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma. BioMed Res. Int. 2017. doi: 10.1155/2017/4698167.Tuo L., Xiang J., Pan X., Gao Q., Zhang G., Yang Y., Liang L., Xia J., Wang K., Tang N. PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway. Front. Oncol. 2018; 8: 611. doi: 10.3389/fonc.2018.00611.Tuo L., Xiang J., Pan X., Gao Q., Zhang G., Yang Y., Liang L., Xia J., Wang K., Tang N. PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway. Front. Oncol. 2018; 8: 611. doi: 10.3389/fonc.2018.00611.Delgobo M., Gonçalves R.M., Delazeri M.A., Falchetti M., Zandoná A., Nascimento das Neves R., Almeida K., Fagundes A.C., Gelain D.P., Fracasso J.I., Macêdo G.B., Priori L., Bassani N., Bishop A.J.R., Forcelini C.M., Moreira J.C.F., Zanotto-Filho A. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. Free Radic Biol Med. 2021; 177: 58–71. doi: 10.1016/j.freeradbiomed.2021.10.020.Delgobo M., Gonçalves R.M., Delazeri M.A., Falchetti M., Zandoná A., Nascimento das Neves R., Almeida K., Fagundes A.C., Gelain D.P., Fracasso J.I., Macêdo G.B., Priori L., Bassani N., Bishop A.J.R., Forcelini C.M., Moreira J.C.F., Zanotto-Filho A. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. Free Radic Biol Med. 2021; 177: 58–71. doi: 10.1016/j.freeradbiomed.2021.10.020.Robledinos-Antón N., Fernández-Ginés R., Manda G., Cuadrado A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. 2019. doi: 10.1155/2019/9372182.Robledinos-Antón N., Fernández-Ginés R., Manda G., Cuadrado A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. 2019. doi: 10.1155/2019/9372182.

The authors declare that there are no conflicts of interest present.